Fulminant post-transplant lymphoproliferative disorder presenting with lactic acidosis and acute liver failure.

Post-transplant lymphoproliferative disorder (PTLD) is the most common non-cutaneous malignancy in solid organ transplant recipients and is associated with significant mortality. In renal transplant recipients the incidence has been estimated to be between 0.2 and 2.3% [1,2]. Most PTLD is driven by Epstein–Barr virus (EBV) infection. The risk of lymphoma in transplant recipients is up to 40 times that of the general population [1]. A spectrum of severity is seen and this reflects the degree of additional oncogene activation and the associated transition from a polyclonal to a monoclonal disease [3]. Extra-nodal disease is common and as a consequence the presentation is often subtle and the diagnosis delayed. There are two principle risk factors for the development of PTLD: the intensity of immunosuppression and the EBV status of the donor and recipient. High dose immunosuppression with ciclosporin, tacrolimus, or anti-lymphocyte antibodies are all associated with increased risk [1]. EBV naive recipients receiving EBV positive grafts are at greatly increased risk [4,5]. Such patients acquire a primary infection in the context of high dose immunosuppression during the early posttransplant period when cytotoxic T-cell responses to EBV are undetectable [6]. This report describes a minimally immunosuppressed patient who developed PTLD very early in the posttransplant period. The clinical presentation was catastrophic and to the best of our knowledge has not been described before. Case

[1]  R. Sokol,et al.  Response of elevated Epstein-Barr virus DNA levels to therapeutic changes in pediatric liver transplant patients: 56-month follow up and outcome , 2002, Transplantation.

[2]  D. Wigle,et al.  Epstein-Barr virus serology and posttransplant lymphoproliferative disease in lung transplantation. , 2001, Transplantation.

[3]  K. Welsh,et al.  Rising incidence of post‐transplant lymphoproliferative disease in kidney transplant recipients , 2001, The British journal of surgery.

[4]  R. Busuttil,et al.  Prevention and preemptive therapy of postransplant lymphoproliferative disease in pediatric liver recipients. , 1998, Transplantation.

[5]  D. Liebowitz Epstein-Barr virus and a cellular signaling pathway in lymphomas from immunosuppressed patients. , 1998, The New England journal of medicine.

[6]  M. Yacoub,et al.  A prospective study in heart and lung transplant recipients correlating persistent Epstein-Barr virus infection with clinical events. , 1997, Transplantation.

[7]  M. Yacoub,et al.  Transmission of donor Epstein-Barr virus (EBV) in transplanted organs causes lymphoproliferative disease in EBV-seronegative recipients. , 1996, The Journal of general virology.

[8]  T. Habermann,et al.  Pretransplantation assessment of the risk of lymphoproliferative disorder. , 1995, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[9]  G Opelz,et al.  Feeding the preterm infant , 1993, The Lancet.

[10]  A. Friedman,et al.  A RECENT DECREASE IN THE TIME TO DEVELOPMENT OF MONOMORPHOUS AND POLYMORPHOUS POSTTRANSPLANT LYMPHOPROLIFERATIVE DISORDER , 1992, Transplantation.